Conducted by leading breast oncologists from UCSF under a grant from the California Breast Cancer Research Program and the University of California , San Francisco Brain Spore, the study will analyze results from cerebrospinal fluid using Biocept’s CNSide™ assay with results from blood samples SAN
More than 99 million healthcare consumers now have access to Biocept's suite of blood-based diagnostics through healthcare payors and plans SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the
SAN DIEGO --(BUSINESS WIRE)-- Biocept, Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer, today announced the voluntary resignation of Bill Kachioff, Senior Vice President and Chief Financial Officer,
Discussion to Feature Applications of Liquid Biopsies to Identify PDL-1 and CMET Expression in Lung Cancer SAN DIEGO --(BUSINESS WIRE)-- Biocept , Inc. (NASDAQ: BIOC), a molecular diagnostics company commercializing and developing liquid biopsies to improve the detection and treatment of cancer,
SAN DIEGO , Oct. 14, 2016 /PRNewswire/ -- Biocept, Inc. ( NASDAQ : BIOC), a molecular diagnostics company commercializing and developing blood-based liquid biopsies to provide information to physicians to improve the diagnosis and treatment of cancer, announces the pricing of an underwritten public
SAN DIEGO , Dec. 9, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy solutions, today announced the pricing of an underwritten public offering of 24,600,000 shares of its common stock (or pre-funded warrants to
SAN DIEGO , April 14, 2020 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, today
SAN DIEGO , Jan. 26, 2018 /PRNewswire/ -- Biocept, Inc . (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of patients diagnosed with cancer, announces
SAN DIEGO , Jan. 18, 2019 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced it has
SAN DIEGO , Sept. 21, 2018 /PRNewswire/ -- Biocept, Inc. (NASDAQ: BIOC) (" Biocept " or the "Company"), a leading commercial provider of liquid biopsy tests designed to provide physicians with clinically actionable information to improve the outcomes of cancer patients, today announced it has